IRTC: Cardiac Monitor King Trading at a Discount After Earnings Overreaction

Signal: WATCHLIST | Score: 46.22/100

iRhythm Technologies crushed earnings in February but got punished anyway, creating a compelling setup for patient investors. With earnings 17 days away and the stock trading 46% below its 52-week high, this medical device leader deserves your attention.

The Setup

IRTC is oversold and coiled for a move. The RSI sits at 38.6, firmly in oversold territory, while the stock trades at $115.24 - just 18% above its 52-week low of $97.16. More telling: shares have drifted 24% lower since that February earnings beat, currently trading near the bottom of the post-earnings range of $113.81-$148.18. This kind of price action after strong fundamentals often signals a classic overreaction that smart money eventually corrects.

The Catalyst

The February 19 earnings report was a blowout that the market completely misread. Revenue hit $208.9 million, beating estimates by 3.4% with explosive 27% year-over-year growth. Adjusted EPS of $0.29 obliterated the $0.06 estimate - that's a 383% beat. Full-year 2025 revenue of $747.1 million represented 26.2% growth, with 2026 guidance calling for $875 million.

But here's the kicker: despite this performance, shares fell 5% the next day and kept sliding. Classic Wall Street myopia. The upcoming Q1 2026 earnings on April 30 could be the catalyst that finally wakes up the market to what they're missing.

Bull Case

Massive growth trajectory: 27% revenue growth in a mature medical device market is exceptional, indicating genuine market share gains in cardiac monitoring
Analyst conviction: Strong buy rating with a $201.71 average price target implies 75% upside from current levels
Earnings momentum: With the bar potentially lowered after the post-earnings sell-off, another beat could trigger significant re-rating

Bear Case

Valuation concerns: 137.8x forward P/E and 4.98x price-to-sales suggest the market may be pricing in perfection
Profitability questions: Negative 5.96% profit margins despite strong revenue growth raise efficiency concerns

The Watch

This isn't a buy yet, but it's earning a prime spot on the watchlist. I'm watching for two triggers: a break above $125 (the midpoint of that post-earnings range) or another earnings beat on April 30 that finally gets the market to pay attention. Either event could spark a rapid move back toward that $148 post-earnings high.

Current price: $115.24 | Target on upgrade: $148+ | Timeframe: 2-3 months

*This is one person's analysis, not financial advice. Always do your own research.*